LOGIN
Clinical Intergroup
Research & Trials
Pathology Panel
Patients
 

Publications

Explore the latest discoveries and publications on Waldenström´s Macroglobulinemia

 

 2024

 2024-04-30 |
Impact of the Presence and Number of Chromosomal Abnormalities on the Clinical Outcome in Waldenström [...]

Impact of the Presence and Number of Chromosomal Abnormalities on the Clinical Outcome in Waldenström Macroglobulinemia: A Monocentric Experience
Danesin, N., L. Bonaldi, A. Martines, S. Nalio, R. Bertorelle, S. Compagno, R. Marcato, S. Manni, F. Scarmozzino, M. Pizzi, A. P. D. Tos, A. Cellini, G. Scapinello, A. Visentin, L. Trentin, and F. Piazza

 2024-04-26 |
High Efficacy of Cd19 Car T-Cells in Patients with Transformed Waldenström Macroglobulinemia.

High Efficacy of Cd19 Car T-Cells in Patients with Transformed Waldenström Macroglobulinemia.
Durot, E., D. Roosweil, A. Chauchet, J. Decroocq, R. Di Blasi, T. Gastinne, H. Bensaber, M. Cheminant, C. Jacquet, S. Guidez, F. X. Gros, E. Bachy, A. Coste, P. Cony-Makhoul, S. P. Treon, A. J. Delmer, R. Reshef, S. Le Gouill, J. J. Castillo, and R. Houot

 2024-04-26 |
Long-Term Outcomes by Bone Marrow B-Cell Depletion from the R2w Trial of Bortezomib with Cyclophosphamide [...]

Long-Term Outcomes by Bone Marrow B-Cell Depletion from the R2w Trial of Bortezomib with Cyclophosphamide and Rituximab in Waldenstrőm Macroglobulinaemia
de Tute, R., N. Counsell, L. Clifton-Hadley, S. D'Sa, G. Pratt, G. Campbell, L. Campbell, R. Sadler, W. Townsend, B. Popova, P. Smith, O. Schofield, R. Owen, and R. Auer

 2024-04-03 |
How to Manage Waldenström's Macroglobulinemia in 2024

How to Manage Waldenström's Macroglobulinemia in 2024
Grunenberg, A. and C. Buske

 2024-04-02 |
When Waldenström Macroglobulinemia Hits the Kidney: Description of a Case Series and Management [...]

When Waldenström Macroglobulinemia Hits the Kidney: Description of a Case Series and Management of a "Rare in Rare" Scenario
Danesin, N., G. Scapinello, D. Del Prete, E. Naso, T. Berno, A. Visentin, L. Bonaldi, A. Martines, R. Bertorelle, F. Vianello, C. Gurrieri, R. Zambello, C. Castellani, M. Fedrigo, S. Rizzo, A. Angelini, L. Trentin, and F. Piazza.

 2024-04-01 |
Circulating Tumor Cells in Waldenström Macroglobulinemia

Circulating Tumor Cells in Waldenström Macroglobulinemia
Boccon-Gibod, C., E. Sourdeau, P. Morel, E. Chapiro, F. Nguyen-Khac, C. Bravetti, F. Davi, V. Morel, N. Gauthier, A. Grenier, I. Boussen, S. Choquet, V. Leblond, M. Le Garff-Tavernier, M. Baron, and D. Roos-Weil.

 2024-03-19 |
Long-Term Results of Waldenström Macroglobulinaemia Treatment by Bendamustine and Rituximab: A [...]

Long-Term Results of Waldenström Macroglobulinaemia Treatment by Bendamustine and Rituximab: A Study on Behalf of the French Innovative Leukemia Organization (Filo)
Laribi, K., S. Poulain, L. Willems, F. Merabet, C. Herbaux, D. Roos-Weil, I. Laribi de Materre, X. Roussel, M. Nudel, S. Tricot, J. Dupuis, R. Le Calloch, B. Bareau, and V. Leblond

 2024-02-02 |
A 74-Year-Old Man with Waldenström Macroglobulinemia and Progressive Dyspnea

A 74-Year-Old Man with Waldenström Macroglobulinemia and Progressive Dyspnea
Tzilas, V., A. G. Nicholson, M. Gavriatopoulou, I. Ntanasis-Stathopoulos, M. A. Dimopoulos, and D. Bouros.

 2024-02-01 |
Single-Cell Analysis of Myd88(L265p) and Myd88(Wt) Waldenström Macroglobulinemia Patients.

Single-Cell Analysis of Myd88(L265p) and Myd88(Wt) Waldenström Macroglobulinemia Patients.
Bagratuni, T., F. Aktypi, O. Theologi, M. Sakkou, K. M. Verrou, N. Mavrianou-Koutsoukou, D. Patseas, C. Liacos, S. Skourti, A. Papadimou, K. Taouxi, F. Theodorakakou, G. Kollias, P. Sfikakis, E. Terpos, M. A. Dimopoulos, and E. Kastritis

 2024-01-03 |
Long-Term Survival in a Patient with Transformation of Waldenström's Macroglobulinemia into Dlbcl

Long-Term Survival in a Patient with Transformation of Waldenström's Macroglobulinemia into Dlbcl
Solia, E., I. Ntanasis-Stathopoulos, E. Kastritis, E. Terpos, M. A. Dimopoulos, and M. Gavriatopoulou

 2024-01-02 |
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, Nccn Clinical Practice [...]

Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, Nccn Clinical Practice Guidelines in Oncology
Kumar, S. K., N. S. Callander, K. Adekola, L. D. Anderson, Jr., M. Baljevic, R. Baz, E. Campagnaro, J. J. Castillo, C. Costello, C. D'Angelo, B. Derman, S. Devarakonda, N. Elsedawy, A. Garfall, K. Godby, J. Hillengass, L. Holmberg, M. Htut, C. A. Huff, M. Hultcrantz, Y. Kang, S. Larson, H. Lee, M. Liedtke, T. Martin, J. Omel, T. Robinson, A. Rosenberg, D. Sborov, M. A. Schroeder, D. Sherbenou, A. Suvannasankha, J. Valent, A. N. Varshavsky-Yanovsky, J. Snedeker, and R. Kumar

 2023

 2023-12-23 |
Frontline Therapy with Bendamustine Rituximab (Br) and Rituximab Cyclophosphamide Vincristine [...]

Frontline Therapy with Bendamustine Rituximab (Br) and Rituximab Cyclophosphamide Vincristine Prednisone (Rcvp) Confers Similar Long-Term Outcomes in Patients with Treatment Naïve Waldenström Macroglobulinemia in a Real-World Setting: A Population-Based Analysis
Kim, J. L., A. S. Gerrie, K. J. Savage, D. Villa, D. Scott, J. W. Craig, P. Farinha, B. Skinnider, G. Slack, J. M. Connors, L. H. Sehn, C. Venner, and C. L. Freeman

 2023-12-11 |
Immunophenotypic Assessment of Clonal Plasma Cells and B-Cells in Bone Marrow and Blood in the [...]

Immunophenotypic Assessment of Clonal Plasma Cells and B-Cells in Bone Marrow and Blood in the Diagnostic Classification of Early Stage Monoclonal Gammopathies: An Istopmm Study.
Pérez-Escurza, O., J. Flores-Montero, JÞ Óskarsson, L. Sanoja-Flores, J. Del Pozo, Q. Lecrevisse, S. Martín, E. R. Reed, G. K. Hákonardóttir, S. Harding, S. Þorsteinsdóttir, S. Rögnvaldsson, T. J. Love, B. Durie, S. Y. Kristinsson, and A. Orfao

 2023-12-06 |
Waldenström Macroglobulinemia: Targeted Agents Taking Center Stage

Waldenström Macroglobulinemia: Targeted Agents Taking Center Stage
Sarosiek, S. and J. J. Castillo

 2023-11-23 |
New Developments in the Diagnosis and Characterization of Waldenström's Macroglobulinemia

New Developments in the Diagnosis and Characterization of Waldenström's Macroglobulinemia
García-Sanz, R., Z. R. Hunter, S. Poulain, M. Varettoni, and R. G. Owen

 2023-11-03 |
Cold agglutinin disease and cryoglobulinaemia: A frequent coexistence with clinical impact

Cold agglutinin disease and cryoglobulinaemia: A frequent coexistence with clinical impact
Jahanzaib Khwaja, Nicole Japzon, Maria Gabriel, Kavin Raju, Vijith Rajaratnam, Rajeev Gupta, Ali Rismani, Chara Kyriakou, Shirley D'Sa

 2023-11-01 |
Clonal Relationship and Mutation Analysis in Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia [...]

Clonal Relationship and Mutation Analysis in Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Associated with Diffuse Large B-Cell Lymphoma
• Berendsen, M. R., D. A. G. van Bladel, E. Hesius, C. Berganza Irusquieta, J. Rijntjes, A. B. van Spriel, E. van der Spek, J. F. M. Pruijt, L. I. Kroeze, K. M. Hebeda, S. Croockewit, W. B. C. Stevens, Jhjm van Krieken, Pjta Groenen, M. van den Brand, and B. Scheijen

 2023-10-27 |
Ibrutinib and Venetoclax as Primary Therapy in Symptomatic Treatment Naïve Waldenström Macrog [...]

Ibrutinib and Venetoclax as Primary Therapy in Symptomatic Treatment Naïve Waldenström Macroglobulinemia
• Castillo, J. J., A. R. Branagan, D. Sermer, C. Flynn, K. E. Meid, M. Little, K. Stockman, T. P. White, A. G. Canning, M. L. Guerrera, A. Kofides, S. Liu, X. Liu, K. Richardson, N. Tsakmaklis, C. J. Patterson, Z. R. Hunter, S. P. Treon, and S. Sarosiek

 2023-10-19 |
Advances in Treatment of Waldenström Macroglobulinemia

Advances in Treatment of Waldenström Macroglobulinemia
Durot, E. and C. Tomowiak

 2023-10-01 |
Waldenström Macroglobulinemia in Very Elderly (≥75-Year-Old) Patients: A 33-Year-Retrospective [...]

Waldenström Macroglobulinemia in Very Elderly (≥75-Year-Old) Patients: A 33-Year-Retrospective Cohort Study in an Italian University Hospital.
Danesin, N., M. Lo Schirico, G. Scapinello, A. Grassi, M. Riva, T. Berno, A. Branca, A. Visentin, M. Carraro, L. Pavan, S. Manni, L. Bonaldi, A. Martines, R. Bertorelle, F. Vianello, C. Gurrieri, C. Briani, R. Zambello, L. Trentin, and F. Piazza.Hemasphere 7, no. 10 (Oct 2023): e964.

 2023-09-13 |
Impact of Circulating Lymphoma Cells at Diagnosis on Outcomes in Patients with Waldenstrom Ma [...]

Impact of Circulating Lymphoma Cells at Diagnosis on Outcomes in Patients with Waldenstrom Macroglobulinemia.
Nalin, A., Q. Zhao, T. Voorhees, D. Bond, Y. Sawalha, W. Hanel, A. Sigmund, K. Annunzio, L. Alinari, R. Baiocchi, K. Maddocks, D. Jones, B. Christian, and N. Epperla. Front Oncol 13 (2023): 1264387.

 2023-09-13 |
MYD88 Wild Type in IgM Monoclonal Gammopathies: From Molecular Mechanisms to Clinical Challenges

MYD88 Wild Type in IgM Monoclonal Gammopathies: From Molecular Mechanisms to Clinical Challenges
Bagratuni, Tina, Alexandra Papadimou, Kostantina Taouxi, Meletios A. Dimopoulos, and Efstathios Kastritis

 2023-09-11 |
Zanubrutinib: Past, Present, and Future.

Zanubrutinib: Past, Present, and Future.
Tam, C. S., J. L. Muñoz, J. F. Seymour, and S. Opat. Blood Cancer J 13, no. 1 (Sep 11 2023): 141.

 2023-09-06 |
Serum Paraprotein Is Associated with Adverse Prognostic Factors and Outcome, across Different [...]

Serum Paraprotein Is Associated with Adverse Prognostic Factors and Outcome, across Different Subtypes of Mature B-Cell Malignancies-a Systematic Review.
Cox, M. C., F. Esposito, M. Postorino, A. Venditti, and A. Di Napoli. Cancers (Basel) 15, no. 18 (Sep 6 2023).

 2023-08-18 |
The Oncogenic Human B-Cell Lymphoma Myd88 L265p Mutation Genocopies Activation by Phosphorylation [...]

The Oncogenic Human B-Cell Lymphoma Myd88 L265p Mutation Genocopies Activation by Phosphorylation at the Toll/Interleukin-1 Receptor (Tir) Domain.
Minderman, M., H. Lantermans, C. van der Zwaan, A. J. Hoogendijk, M. van den Biggelaar, M. J. Kersten, M. Spaargaren, and S. T. Pals. Blood Cancer J 13, no. 1 (Aug 18 2023): 125.

 2023-08-17 |
Inflammation Is Predictive of Outcome in Waldenström Macroglobulinemia Treated by Bruton Tyrosine [...]

Inflammation Is Predictive of Outcome in Waldenström Macroglobulinemia Treated by Bruton Tyrosine Kinase Inhibitors: A Multicentric Real-Life Study.
Debureaux, P. E., N. Forgeard, D. Elessa, S. Harel, L. Frenzel, B. Royer, A. Talbot, S. Choquet, F. Davi, F. Nguyen-Khac, W. Cuccuini, M. Cheminant, C. Bravetti, G. Lazarian, S. Kaltenbach, O. Hermine, D. Roos-Weil, M. Espéli, K. Balabanian, and B. Arnulf. Haematologica (Aug 17 2023).

 2023-08-17 |
Leukemic Involvement Is a Common Feature in Waldenström Macroglobulinemia at Diagnosis.

Leukemic Involvement Is a Common Feature in Waldenström Macroglobulinemia at Diagnosis.
Montesdeoca, S., N. García-Gisbert, X. Calvo, L. Arenillas, D. Román, C. Fernández-Rodríguez, R. Navarro, B. Costan, M. D. C. Vela, L. Camacho, E. Abella, L. Colomo, M. Salido, A. Puiggros, L. Florensa, B. Espinet, B. Bellosillo, and A. Ferrer Del Álamo. Cancers (Basel) 15, no. 16 (Aug 17 2023).

 2023-08-12 |
Biomarkers of Progression and Risk Stratification in Asymptomatic Waldenström Macroglobulinemia.

Biomarkers of Progression and Risk Stratification in Asymptomatic Waldenström Macroglobulinemia.
Bustoros, M., C. Gribbin, J. J. Castillo, and R. Furman. Hematol Oncol Clin North Am (Aug 12 2023).

 2023-08-01 |
Investigation and Management of Immunoglobulin M- and Waldenström-Associated Peripheral Neuro [...]

Investigation and Management of Immunoglobulin M- and Waldenström-Associated Peripheral Neuropathies.
Tomkins, O., V. Leblond, M. P. Lunn, K. Viala, D. R. Weil, and S. D'Sa. Hematol Oncol Clin North Am 37, no. 4 (Aug 2023): 761-76.

 2023-08-01 |
Clonal Architecture and Evolutionary History of Waldenström's Macroglobulinemia at the Single-Cell [...]

Clonal Architecture and Evolutionary History of Waldenström's Macroglobulinemia at the Single-Cell Level.
García-Sanz, R., M. García-Álvarez, A. Medina, E. Askari, V. González-Calle, M. Casanova, I. de la Torre-Loizaga, F. Escalante-Barrigón, M. Bastos-Boente, A. Bárez, N. Vidaña-Bedera, J. M. Alonso, M. E. Sarasquete, M. González, M. C. Chillón, M. Alcoceba, and C. Jiménez. Dis Model Mech 16, no. 8 (Aug 1 2023).

 2023-07-21 |
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis from [...]

Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis from the Randomized Phase Iii Aspen Study.
Dimopoulos, M. A., S. Opat, S. D'Sa, W. Jurczak, H. P. Lee, G. Cull, R. G. Owen, P. Marlton, B. E. Wahlin, R. Garcia-Sanz, H. McCarthy, S. Mulligan, A. Tedeschi, J. J. Castillo, J. Czyz, C. Fernández de Larrea, D. Belada, E. Libby, J. Matous, M. Motta, T. Siddiqi, M. Tani, M. Trněný, M. C. Minnema, C. Buske, V. Leblond, S. P. Treon, J. Trotman, W. Y. Chan, J. Schneider, H. Allewelt, S. Patel, A. Cohen, and C. S. Tam. J Clin Oncol (Jul 21 2023): Jco2202830.

 2023-07-17 |
Recent Updates in the Indolent Lymphomas: Update on Marginal Zone Lymphoma and Waldenström's [...]

Recent Updates in the Indolent Lymphomas: Update on Marginal Zone Lymphoma and Waldenström's Macroglobulinemia.
Amaador, K., C. Thieblemont, J. Trotman, and M. C. Minnema. Hematol Oncol (Jul 17 2023).

 2023-06-21 |
Immune Response to Covid-19 Vaccination in Patients with Waldenström Macroglobulinaemia Who Pause [...]

Immune Response to Covid-19 Vaccination in Patients with Waldenström Macroglobulinaemia Who Pause Their Btki Therapy.
Rankin, K., P. Hastak, A. Wong, S. C. Sasson, B. Beaton, A. Yeola, A. Warden, S. Turville, A. D. Kelleher, F. Brilot, and J. Trotman. eJHaem 4, no. 3 (Aug 2023): 728-32.

 2023-06-01 |
Sars-Cov-2 Infection in Patients with Waldenström's Macroglobulinemia: A Multicenter International [...]

Sars-Cov-2 Infection in Patients with Waldenström's Macroglobulinemia: A Multicenter International Cohort Study.
Defrancesco, I., V. V. Ferretti, P. Morel, C. Kyriakou, E. Kastritis, I. Tohidi-Esfahani, A. Tedeschi, C. Buske, R. García-Sanz, J. M. I. Vos, V. Peri, G. Margiotta Casaluci, A. Ferrari, F. Piazza, R. Oostvogels, E. Lovato, L. Montes, L. M. Fornecker, A. Grunenberg, M. A. Dimopoulos, C. S. Tam, S. D'Sa, V. Leblond, J. Trotman, F. Passamonti, L. Arcaini, and M. Varettoni. Hemasphere 7, no. 6 (Jun 2023): e887.

 2023-06-01 |
Future Directions in the Frontline Management of Waldenström Macroglobulinemia.

Future Directions in the Frontline Management of Waldenström Macroglobulinemia.
Buske, C. and M. L. Palomba. Hematol Oncol Clin North Am (Jun 1 2023).

 2023-06-01 |
Dose of Ibrutinib in Waldenström Macroglobulinaemia: Less Can Be More

Dose of Ibrutinib in Waldenström Macroglobulinaemia: Less Can Be More
Tohidi-Esfahani, I. and J. Trotman. Br J Haematol (Jan 30 2023).

 2023-06-01 |
The Rory Morrison Wmuk Registry for Waldenström Macroglobulinaemia: The Growth of a National Registry [...]

The Rory Morrison Wmuk Registry for Waldenström Macroglobulinaemia: The Growth of a National Registry for a Rare Disorder
Uppal, E., J. Khwaja, J. Bomsztyk, H. McCarthy, J. Kothari, P. Walton, H. Scorer, C. Kyriakou, D. El-Sharkawi, and S. D'Sa. Br J Haematol (Jan 25 2023).

 2023-05-29 |
Evaluation and Management of Bing-Neel Syndrome.

Evaluation and Management of Bing-Neel Syndrome.
Schep, S. J., J. M. I. Vos, and M. C. Minnema. Hematol Oncol Clin North Am (May 29 2023).

 2023-05-29 |
Sustained Inhibition of Complement C1s with Sutimlimab over 2 Years in Patients with Cold [...]

Sustained Inhibition of Complement C1s with Sutimlimab over 2 Years in Patients with Cold Agglutinin Disease.
Röth, A., W. Barcellini, S. D'Sa, Y. Miyakawa, C. M. Broome, M. Michel, D. J. Kuter, B. Jilma, T. H. A. Tvedt, I. C. Weitz, R. Yoo, D. Jayawardene, D. S. Vagge, K. Kralova, F. Shafer, M. Wardȩcki, M. Lee, and S. Berentsen. Am J Hematol (May 29 2023).

 2023-05-26 |
Btk Inhibitors in the Frontline Management of Waldenström Macroglobulinemia.

Btk Inhibitors in the Frontline Management of Waldenström Macroglobulinemia.
Varettoni, M. and J. V. Matous. Hematol Oncol Clin North Am (May 26 2023).

 2023-05-26 |
The Management of Relapsed or Refractory Waldenström's Macroglobulinemia.

The Management of Relapsed or Refractory Waldenström's Macroglobulinemia.
García-Sanz, R. and A. Tedeschi. Hematol Oncol Clin North Am (May 26 2023).

 2023-05-26 |
Evaluation and Management of Disease Transformation in Waldenström Macroglobulinemia.

Evaluation and Management of Disease Transformation in Waldenström Macroglobulinemia.
Talaulikar, D., C. Tomowiak, E. Toussaint, P. Morel, P. Kapoor, J. J. Castillo, A. Delmer, and E. Durot. Hematol Oncol Clin North Am (May 26 2023).

 2023-05-25 |
Targeting the Immune Microenvironment in Waldenström Macroglobulinemia Via Halting the Cd40/Cd40-Ligand [...]

Targeting the Immune Microenvironment in Waldenström Macroglobulinemia Via Halting the Cd40/Cd40-Ligand Axis
Sacco, A., V. Desantis, J. Celay, V. Giustini, F. Rigali, F. D. Savino, M. Cea, D. Soncini, A. Cagnetta, A. G. Solimando, D. D'Aliberti, S. Spinelli, D. Ramazzotti, C. Almici, K. Todoerti, A. Neri, A. Anastasia, A. Tucci, M. Motta, M. Chiarini, Y. Kawano, J. A. Martinez-Climent, R. Piazza, and A. M. Roccaro. Blood (Feb 3 2023).

 2023-05-19 |
Proteasome Inhibitor-Based Regimens in the Frontline Management of Waldenström Macroglobulinemia.

Proteasome Inhibitor-Based Regimens in the Frontline Management of Waldenström Macroglobulinemia.
Solia, E., M. A. Dimopoulos, and E. Kastritis. Hematol Oncol Clin North Am (May 19 2023).

 2023-05-11 |
Unmet Clinical Needs in the Use of Zanubrutinib in Malignant Lymphomas (Waldenström Macroglobulinemia, [...]

Unmet Clinical Needs in the Use of Zanubrutinib in Malignant Lymphomas (Waldenström Macroglobulinemia, Marginal Zone Lymphoma and Mantle Cell Lymphoma): A Consensus-Based Position Paper from an Ad Hoc Expert Panel.
Zinzani, P. L., F. R. Mauro, A. Tedeschi, M. Varettoni, F. Zaja, and G. Barosi. "Unmet Clinical Needs in the Use of Zanubrutinib in Malignant Lymphomas (Waldenström Macroglobulinemia, Marginal Zone Lymphoma and Mantle Cell Lymphoma): A Consensus-Based Position Paper from an Ad Hoc Expert Panel." Hematol Oncol (May 11 2023).

 2023-05-01 |
Systematic Literature Review of Quality-of-Life Questionnaires in Waldenström Macroglobulinaemia [...]

Systematic Literature Review of Quality-of-Life Questionnaires in Waldenström Macroglobulinaemia - Need for a Disease-Specific Tool.
Bristogiannis, Sotirios, Jahanzaib Khwaja, Yadanar Lwin, Encarl Uppal, Shirley D'Sa, and Charalampia Kyriakou. eJHaem n/a, no. n/a

 2023-04-23 |
Highly Sensitive Detection Method of Cxcr4 Tumor Hotspot Mutations by Drop-Off Droplet Digital [...]

Highly Sensitive Detection Method of Cxcr4 Tumor Hotspot Mutations by Drop-Off Droplet Digital Pcr in Patients with Igm Monoclonal Gammopathies.
Markou, A. N., T. Bagratuni, C. Tsakiri, V. Tserpeli, S. Skourti, N. M. Koutsoukou, A. Papadimou, E. Terpos, E. Kastritis, E. Lianidou, and M. A. Dimopoulos. J Mol Diagn (Apr 23 2023).

 2023-04-20 |
Report of Consensus Panel 4 from the 11th International Workshop on Waldenstrom's Macroglobulinemia [...]

Report of Consensus Panel 4 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on Diagnostic and Response Criteria.
Treon, S. P., A. Tedeschi, J. San-Miguel, R. Garcia-Sanz, K. C. Anderson, E. Kimby, M. C. Minnema, G. Benevolo, L. Qiu, S. Yi, E. Terpos, C. S. Tam, J. J. Castillo, P. Morel, M. Dimopoulos, and R. G. Owen. Semin Hematol (Apr 20 2023).

 2023-04-12 |
Myd88 L265p Mutation Detection by Ddpcr: Recommendations for Screening and Minimal Residual Disease [...]

Myd88 L265p Mutation Detection by Ddpcr: Recommendations for Screening and Minimal Residual Disease Monitoring : Ddpcr for Highly Sensitive Detection of Myd88 L265p Mutation.
Drandi, D., M. Ferrante, M. Borriero, and S. Ferrero. Methods Mol Biol 2621 (2023): 57-72.

 2023-04-06 |
Report of Consensus Panel 3 from the 11th International Workshop on Waldenström's Macroglobulinemia: [...]

Report of Consensus Panel 3 from the 11th International Workshop on Waldenström's Macroglobulinemia: Recommendations for Molecular Diagnosis in Waldenström's Macroglobulinemia.
Garcia-Sanz, R., M. Varettoni, C. Jiménez, S. Ferrero, S. Poulain, J. F. San-Miguel, M. L. Guerrera, D. Drandi, T. Bagratuni, M. McMaster, A. M. Roccaro, D. Roos-Weil, M. Leiba, Y. Li, L. Qiu, J. Hou, C. F. De Larrea, J. J. Castillo, M. Dimopoulos, R. G. Owen, S. P. Treon, and Z. R. Hunter. Semin Hematol (Apr 6 2023).

 2023-03-29 |
Report of Consensus Panel 5 from the 11th International Workshop on Waldenstrom's Macroglobulinemia [...]

Report of Consensus Panel 5 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on Covid-19 Prophylaxis and Management.
Terpos, E., A. R. Branagan, R. García-Sanz, J. Trotman, L. M. Greenberger, D. M. Stephens, P. Morel, E. Kimby, A. M. Frustaci, E. Hatjiharissi, J. San-Miguel, M. A. Dimopoulos, S. P. Treon, and V. Leblond. Semin Hematol (Mar 29 2023).

 2023-03-29 |
Report of Consensus Panel 1 from the 11(Th) International Workshop on Waldenstrom's Macroglobulinemia [...]

Report of Consensus Panel 1 from the 11(Th) International Workshop on Waldenstrom's Macroglobulinemia on Management of Symptomatic, Treatment-Naïve Patients.
Buske, C., J. J. Castillo, J. P. Abeykoon, R. Advani, S. O. Arulogun, A. R. Branagan, X. Cao, S. D'Sa, J. Hou, P. Kapoor, E. Kastritis, M. J. Kersten, V. LeBlond, M. Leiba, J. V. Matous, J. Paludo, L. Qiu, C. S. Tam, A. Tedeschi, S. K. Thomas, I. Tohidi-Esfahani, M. Varettoni, J. M. Vos, R. Garcia-Sanz, J. San-Miguel, M. A. Dimopoulos, S. P. Treon, and J. Trotman. Semin Hematol (Mar 29 2023).

 2023-03-29 |
Report of Consensus Panel 6 from the 11 Th International Workshop on Waldenström's Macroglobulinemia [...]

Report of Consensus Panel 6 from the 11 Th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis.
Merlini, G., S. Sarosiek, G. Benevolo, X. Cao, M. Dimopoulos, R. Garcia-Sanz, M. E. Gatt, C. Fernandez de Larrea, J. San-Miguel, S. P. Treon, and M. C. Minnema. Semin Hematol (Mar 29 2023).

 2023-03-27 |
Report of Consensus Panel 2 from the 11th International Workshop on Waldenström's Macroglobulinemia [...]

Report of Consensus Panel 2 from the 11th International Workshop on Waldenström's Macroglobulinemia on the Management of Relapsed or Refractory Wm Patients.
D'Sa, S., J. V. Matous, R. Advani, C. Buske, J. J. Castillo, M. Gatt, P. Kapoor, M. J. Kersten, V. Leblond, M. Leiba, M. L. Palomba, J. Paludo, L. Qiu, S. Sarosiek, M. Shadman, D. Talaulikar, C. S. Tam, A. Tedeschi, S. K. Thomas, I. Tohidi-Esfahani, J. Trotman, M. Varettoni, J. Vos, R. Garcia-Sanz, J. San-Miguel, M. A. Dimopoulos, S. P. Treon, and E. Kastritis. Semin Hematol (Mar 27 2023).

 2023-03-24 |
Report of Consensus Panel 7 from the 11th International Workshop on Waldenström Macroglobulinemia [...]

Report of Consensus Panel 7 from the 11th International Workshop on Waldenström Macroglobulinemia on Priorities for Novel Clinical Trials.
Tam, C. S., P. Kapoor, J. J. Castillo, C. Buske, S. M. Ansell, A. R. Branagan, E. Kimby, Y. Li, M. L. Palomba, L. Qiu, M. Shadman, J. P. Abeykoon, S. Sarosiek, J. Vos, S. Yi, D. Stephens, D. Roos-Weil, A. M. Roccaro, P. Morel, N. C. Munshi, K. C. Anderson, J. San-Miguel, R. Garcia-Sanz, M. A. Dimopoulos, S. P. Treon, and M. J. Kersten. Semin Hematol (Mar 24 2023).

 2023-02-23 |
Plain Language Summary of the Innovate Study: Ibrutinib Plus Rituximab Is Well-Tolerated and Effective [...]

Plain Language Summary of the Innovate Study: Ibrutinib Plus Rituximab Is Well-Tolerated and Effective in People with Waldenström's Macroglobulinemia
Buske, C., A. Tedeschi, J. Trotman, R. García-Sanz, D. MacDonald, V. Leblond, B. Mahe, C. Herbaux, J. V. Matous, C. S. Tam, L. T. Heffner, M. Varettoni, M. L. Palomba, C. Shustik, E. Kastritis, S. P. Treon, J. Ping, B. Hauns, I. Arango-Hisijara, and M. A. Dimopoulos. Future Oncol (Feb 23 2023).

 2023-02-16 |
Born in the Uk: A Registry to Improve and Broadcast Knowledge on Waldenström Macroglobulinaemia

Born in the Uk: A Registry to Improve and Broadcast Knowledge on Waldenström Macroglobulinaemia
Durot, E. and A. Delmer. Br J Haematol (Feb 16 2023).

 2023-02-10 |
Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's [...]

Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia
Buske, C., M. A. Dimopoulos, A. Grunenberg, E. Kastritis, C. Tomowiak, B. Mahé, X. Troussard, R. Hajek, A. Viardot, O. Tournilhac, T. Aurran, S. Lepretre, H. Zerazhi, B. Hivert, V. Leblond, S. de Guibert, L. Brandefors, R. Garcia-Sanz, M. Gomes da Silva, E. Kimby, B. Schmelzle, D. Kaszynski, J. Dreyhaupt, R. Muche, and P. Morel. J Clin Oncol (Feb 10 2023): Jco2201805.

 2023-02-01 |
Patient Preferences Regarding Treatment Options for Waldenström's Macroglobulinemia: A Discrete [...]

Patient Preferences Regarding Treatment Options for Waldenström's Macroglobulinemia: A Discrete Choice Experiment
Amaador, K., P. T. Nieuwkerk, M. C. Minnema, M. J. Kersten, and J. M. I. Vos. Cancer Med 12, no. 3 (Feb 2023): 3376-86.

 2023-02-01 |
Patient Reported Outcome Measures in Waldenström Macroglobulinaemia: A Real-World Data Analysis [...]

Patient Reported Outcome Measures in Waldenström Macroglobulinaemia: A Real-World Data Analysis from the Wmuk Rory Morrison Registry
Khwaja, J., E. Uppal, S. Bristogiannis, H. McCarthy, J. Kothari, A. Rismani, H. Scorer, J. Nicholson, D. El-Sharkawi, S. D'Sa, and C. Kyriakou. EJHaem 4, no. 1 (Feb 2023): 221-25.

 2023-02-01 |
Bruton Tyrosine Kinase Inhibitors in the Management of Waldenström Macroglobulinemia

Bruton Tyrosine Kinase Inhibitors in the Management of Waldenström Macroglobulinemia
Castillo, J. J., C. Buske, J. Trotman, S. Sarosiek, and S. P. Treon. Am J Hematol 98, no. 2 (Feb 2023): 338-47.

 2023-02-01 |
Diagnostics in Waldenström's Macroglobulinemia: A Consensus Statement of the European Consortium [...]

Diagnostics in Waldenström's Macroglobulinemia: A Consensus Statement of the European Consortium for Waldenström's Macroglobulinemia
Dogliotti, I., C. Jiménez, M. Varettoni, D. Talaulikar, T. Bagratuni, M. Ferrante, J. Pérez, D. Drandi, N. Puig, M. Gilestro, M. García-Álvarez, R. Owen, W. Jurczak, A. Tedeschi, V. Leblond, E. Kastritis, M. J. Kersten, S. D'Sa, M. Kaščák, W. Willenbacher, A. M. Roccaro, S. Poulain, P. Morel, C. Kyriakou, F. Fend, J. M. I. Vos, M. A. Dimopoulos, C. Buske, S. Ferrero, and R. García-Sanz. Leukemia 37, no. 2 (Feb 2023): 388-95.

 2023-01-01 |
Waldenström Disease: News and Perspectives in 2022

Waldenström Disease: News and Perspectives in 2022
Bouclet, F., D. Krzisch, V. Leblond, C. Tomowiak, K. Laribi, L. Ysebaert, O. Tournilhac, C. Dartigeas, S. Leprêtre, and L. Jondreville. Bull Cancer 110, no. 1 (Jan 2023): 88-100.

 2023-01-01 |
Treatment of Relapsed and Refractory Waldenstrom Macroglobulinemia

Treatment of Relapsed and Refractory Waldenstrom Macroglobulinemia
Amaador, K., M. J. Kersten, M. C. Minnema, and J. M. I. Vos. Leuk Lymphoma 64, no. 1 (Jan 2023): 30-41.

 2023-01-01 |
Patients with Treated Indolent Lymphomas Immunized with Bnt162b2 Have Reduced Anti-Spike Neutralizing [...]

Patients with Treated Indolent Lymphomas Immunized with Bnt162b2 Have Reduced Anti-Spike Neutralizing Igg to Sars-Cov-2 Variants, but Preserved Antigen-Specific T Cell Responses
Beaton, B., S. C. Sasson, K. Rankin, J. Raedemaeker, A. Wong, P. Hastak, C. Phetsouphanh, A. Warden, V. Klemm, C. M. L. Munier, A. C. Hoppe, F. Tea, A. Pillay, A. O. Stella, A. Aggarwal, O. Lavee, I. D. Caterson, S. Turville, A. D. Kelleher, F. Brilot, and J. Trotman. Am J Hematol 98, no. 1 (Jan 2023): 131-39.

 2023-01-01 |
Managing Waldenström's Macroglobulinemia with Btk Inhibitors

Managing Waldenström's Macroglobulinemia with Btk Inhibitors
Buske, C., W. Jurczak, J. E. Salem, and M. A. Dimopoulos. Leukemia 37, no. 1 (Jan 2023): 35-46.

 2022

 2022-11-28 |
Clinical Practice Update from the Myeloma Foundation of Australia Medical and Scientific Advisory [...]

Clinical Practice Update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group
Talaulikar, D., D. Joshua, P. J. Ho, J. Gibson, H. Quach, S. Gibbs, S. Ling, C. Ward, B. Augustson, J. Trotman, S. J. Harrison, and C. S. Tam. "Treatment of Patients with Waldenström Macroglobulinaemia: Intern Med J (Nov 28 2022).

 2022-11-28 |
Treatment of Patients with Waldenström Macroglobulinaemia: Clinical Practice Update from the Myeloma [...]

Treatment of Patients with Waldenström Macroglobulinaemia: Clinical Practice Update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group
Talaulikar, D., D. Joshua, P. J. Ho, J. Gibson, H. Quach, S. Gibbs, S. Ling, C. Ward, B. Augustson, J. Trotman, S. J. Harrison, and C. S. Tam. Intern Med J (Nov 28 2022).

 2022-11-25 |
Low Spike Antibody Levels and Impaired Ba.4/5 Neutralization in Patients with Multiple Myeloma [...]

Low Spike Antibody Levels and Impaired Ba.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstrom's Macroglobulinemia after Bnt162b2 Booster Vaccination
Rosati, M., E. Terpos, J. Bear, R. Burns, S. Devasundaram, I. Ntanasis-Stathopoulos, M. Gavriatopoulou, E. Kastritis, M. A. Dimopoulos, G. N. Pavlakis, and B. K. Felber. Cancers (Basel) 14, no. 23 (Nov 25 2022).

 2022-11-04 |
Waldenström Macroglobulinemia Whole Genome Reveals Prolonged Germinal Center Activity and Late [...]

Waldenström Macroglobulinemia Whole Genome Reveals Prolonged Germinal Center Activity and Late Copy Number Aberrations
Maclachlan, K. H., T. Bagratuni, E. Kastritis, B. Ziccheddu, S. X. Lu, V. Yellapantula, C. A. Famulare, K. V. Argyropoulos, A. Derkach, E. Papaemmanuil, A. Dogan, A. M. Lesokhin, S. Z. Usmani, O. Landgren, M. L. Palomba, F. Maura, and M. A. Dimopoulos. Blood Adv (Nov 4 2022).

 2022-11-01 |
Inflammation in Waldenström MacroglobulinAssociated with 6q Deletion and Need for Treatment I [...]

Inflammation in Waldenström MacroglobulinAssociated with 6q Deletion and Need for Treatment Initiation
Forgeard, N., M. Baron, J. Caron, C. Boccon-Gibod, D. Krzisch, N. Guedes, V. Morel, N. Jacque, M. Ouzegdouh, S. Choquet, C. Bravetti, F. Nguyen-Khac, E. Chapiro, V. Leblond, and D. Roos-Weil. Haematologica 107, no. 11 (Nov 1 2022): 2720-24.

 2022-11-01 |
Bortezomib-Based Therapy Is Effective and Well Tolerated in Frontline and Multiply Pre-Treated [...]

Bortezomib-Based Therapy Is Effective and Well Tolerated in Frontline and Multiply Pre-Treated Waldenström Macroglobulinaemia Including Btki Failures: A Real-World Analysis
Khwaja, J., E. Uppal, R. Baker, K. Trivedi, A. Rismani, R. Gupta, I. Proctor, C. Kyriakou, and S. D'Sa. EJHaem 3, no. 4 (Nov 2022): 1330-34.

 2022-10-11 |
Molecular Remission Is an Independent Predictor of Progression-Free Survival in Patients with [...]

Molecular Remission Is an Independent Predictor of Progression-Free Survival in Patients with Waldenström Macroglobulinemia Treated with Chemo-Immunotherapy: Results from the Fil_Biowm Study
Varettoni, M., S. Zibellini, M. Merli, D. Drandi, C. Jiménez, D. Furlan, V. V. Ferretti, N. Fabbri, I. Dogliotti, C. Varraso, M. Ferrante, E. Cappello, V. Peri, C. Cavalloni, M. Borriero, G. V. Facchetti, S. Ferrero, L. Arcaini, and R. Garcia-Sanz. Hematol Oncol (Oct 11 2022).

 2022-10-01 |
Sars-Cov-2 Humoral Responses Following Booster Bnt162b2 Vaccination in Patients with B-Cell M [...]

Sars-Cov-2 Humoral Responses Following Booster Bnt162b2 Vaccination in Patients with B-Cell Malignancies
Terpos, E., D. Fotiou, V. Karalis, I. Ntanasis-Stathopoulos, A. D. Sklirou, M. Gavriatopoulou, P. Malandrakis, V. A. Iconomidou, E. Kastritis, I. P. Trougakos, and M. A. Dimopoulos. Am J Hematol 97, no. 10 (Oct 2022): 1300-08.

 2022-09-13 |
Pooled Safety Analysis of Zanubrutinib Monotherapy in Patients with B-Cell Malignancies. Blood [...]

Pooled Safety Analysis of Zanubrutinib Monotherapy in Patients with B-Cell Malignancies. Blood Adv. 2022;6(4):1296-1308
Tam Cs, Dimopoulos M, Garcia-Sanz R, Et al. Blood Adv 6, no. 17 (Sep 13 2022): 4983.

 2022-09-12 |
Therapeutic Activation of G Protein-Coupled Estrogen Receptor 1 in Waldenström Macroglobulinemia

Therapeutic Activation of G Protein-Coupled Estrogen Receptor 1 in Waldenström Macroglobulinemia
Morelli, E., Z. R. Hunter, M. Fulciniti, A. Gullà, I. D. Perrotta, V. Zuccalà, C. Federico, G. Juli, M. Manzoni, D. Ronchetti, E. Romeo, M. E. Gallo Cantafio, D. Soncini, L. Maltese, M. Rossi, A. M. Roccaro, M. Cea, P. Tassone, A. Neri, S. C. Treon, N. C. Munshi, G. Viglietto, and N. Amodio. Exp Hematol Oncol 11, no. 1 (Sep 12 2022): 54.

 2022-09-01 |
Igm Monoclonal Gammopathies of Clinical Significance: Diagnosis and Management

Igm Monoclonal Gammopathies of Clinical Significance: Diagnosis and Management
Khwaja, J., S. D'Sa, M. C. Minnema, M. J. Kersten, A. Wechalekar, and J. M. Vos. Haematologica 107, no. 9 (Sep 1 2022): 2037-50.

 2022-08-01 |
Use of Btk Inhibitors with Special Focus on Ibrutinib in Waldenström Macroglobulinemia: An Expert [...]

Use of Btk Inhibitors with Special Focus on Ibrutinib in Waldenström Macroglobulinemia: An Expert Panel Opinion Statement
Ferrero, S., M. Gentile, L. Laurenti, F. R. Mauro, M. Martelli, P. Sportoletti, C. Visco, P. L. Zinzani, A. Tedeschi, and M. Varettoni. Hematol Oncol 40, no. 3 (Aug 2022): 332-40.

 2022-08-01 |
Does Early Disease Progression Predict Survival after First Line-Treatment of Waldenström Mac [...]

Does Early Disease Progression Predict Survival after First Line-Treatment of Waldenström Macroglobulinemia?
Labreuche, J., D. Assouan, E. Durot, C. Tomowiak, D. Roos-Weil, E. Toussaint, F. Bijou, R. Lemal, A. Brion, K. Laribi, L. Ysebaert, A. Duhamel, and P. Morel. Hematol Oncol 40, no. 3 (Aug 2022): 400-08.

 2022-07-01 |
Serum Neurofilament Light Chain, Contactin-1 and Complement Activation in Anti-Mag Igm Paraprotein-Related [...]

Serum Neurofilament Light Chain, Contactin-1 and Complement Activation in Anti-Mag Igm Paraprotein-Related Peripheral Neuropathy
Amaador, K., L. Wieske, M. J. A. Koel-Simmelink, A. Kamp, I. Jongerius, K. de Heer, C. E. Teunissen, M. C. Minnema, N. C. Notermans, F. Eftimov, M. J. Kersten, and J. M. I. Vos. J Neurol 269, no. 7 (Jul 2022): 3700-05.

 2022-07-01 |
Dutch Physician's Perspectives on Diagnosis and Treatment of Waldenström's Macroglobulinemia before [...]

Dutch Physician's Perspectives on Diagnosis and Treatment of Waldenström's Macroglobulinemia before and after the Implementation of a National Guideline.
Amaador, K., M. J. Kersten, M. C. Minnema, and J. M. I. Vos. Hemasphere 6, no. 7 (Jul 2022): e746.

 2022-06-28 |
High Frequency of Central Nervous System Involvement in Transformed Waldenström Macroglobulinemia

High Frequency of Central Nervous System Involvement in Transformed Waldenström Macroglobulinemia
Durot, E., L. Kanagaratnam, S. Zanwar, E. Toussaint, E. Kastritis, S. D'Sa, M. Alcoceba, C. Tomowiak, B. Hivert, C. Protin, J. P. Abeykoon, J. M. I. Vos, A. S. Michallet, C. Rodier, J. Dupuis, S. Leprêtre, F. Merabet, X. Roussel, J. M. Zini, C. Regny, A. Patel, P. Morel, D. Roos-Weil, S. P. Treon, M. A. Dimopoulos, R. Garcia-Sanz, P. Kapoor, J. J. Castillo, and A. J. Delmer. Blood Adv 6, no. 12 (Jun 28 2022): 3655-58.

 2022-06-01 |
T-Cell Subset Composition and Functionality in Patients with Waldenström's Macroglobulinemia

T-Cell Subset Composition and Functionality in Patients with Waldenström's Macroglobulinemia
Amaador, K., A. Martens, R. de Boer, J. Rietveld, M. Heemskerk, C. E. Rutten, E. Eldering, M. J. Kersten, A. P. Kater, J. Vos, and S. Tonino. Leuk Lymphoma 63, no. 6 (Jun 2022): 1469-73.

 2022-05-16 |
Myd88 Mutations: Transforming the Landscape of Igm Monoclonal Gammopathies.

Myd88 Mutations: Transforming the Landscape of Igm Monoclonal Gammopathies.
Alcoceba, M., M. García-Álvarez, A. Medina, R. Maldonado, V. González-Calle, M. C. Chillón, M. E. Sarasquete, M. González, R. García-Sanz, and C. Jiménez. Int J Mol Sci 23, no. 10 (May 16 2022).

 2022-05-01 |
A Phase-Ii Study of Atezolizumab in Combination with Obinutuzumab or Rituximab for Relapsed or [...]

A Phase-Ii Study of Atezolizumab in Combination with Obinutuzumab or Rituximab for Relapsed or Refractory Mantle Cell or Marginal Zone Lymphoma or Waldenström's Macroglobulinemia
Panayiotidis, P., G. Tumyan, C. Thieblemont, V. V. Ptushkin, A. Marin-Niebla, R. García-Sanz, S. Le Gouill, A. Stathis, A. Bottos, H. Hamidi, P. Katz, T. Perretti, J. C. Willis, and C. Buske. Leuk Lymphoma 63, no. 5 (May 2022): 1058-69.

 2022-05-01 |
Mast Cell Density and Its Clinical Relevance in Waldenström's Macroglobulinemia

Mast Cell Density and Its Clinical Relevance in Waldenström's Macroglobulinemia
Lemal, R., S. Poulain, A. Ledoux-Pilon, L. Veronese, A. Tchirkov, B. Lebecque, T. Tassin, J. O. Bay, F. Charlotte, F. Nguyen-Khac, M. Berger, C. Godfraind, L. Ysebaert, F. Davi, B. Pereira, V. Leblond, O. Hermine, R. Guièze, F. Pagès, and O. Tournilhac. EJHaem 3, no. 2 (May 2022): 371-78.

 2022-05-01 |
Response to Vaccination against Sars-Cov-2 in 168 Patients with Waldenström Macroglobulinaemia: [...]

Response to Vaccination against Sars-Cov-2 in 168 Patients with Waldenström Macroglobulinaemia: A French Innovative Leukaemia Organization Study
Tomowiak, C., V. Leblond, K. Laribi, M. Baron, C. Puppinck, P. Gérard, E. Courret, G. Gorochov, D. Sterlin, O. Tournilhac, P. Morel, F. Cymbalista, and D. Roos-Weil. Br J Haematol 197, no. 4 (May 2022): 424-27.

 2022-05-01 |
Low Neutralizing Antibody Responses in Wm, Cll and Nhl Patients after the First Dose of the Bnt162b2 [...]

Low Neutralizing Antibody Responses in Wm, Cll and Nhl Patients after the First Dose of the Bnt162b2 and Azd1222 Vaccine
Gavriatopoulou, M., E. Terpos, E. Kastritis, A. Briasoulis, S. Gumeni, I. Ntanasis-Stathopoulos, A. D. Sklirou, P. Malandrakis, E. Eleutherakis-Papaiakovou, M. Migkou, I. P. Trougakos, and M. A. Dimopoulos. Clin Exp Med 22, no. 2 (May 2022): 319-23.

 2022-04-12 |
Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and Igm-Mgus: Current Insights and Clinical [...]

Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and Igm-Mgus: Current Insights and Clinical Relevance
Drandi, D., P. Decruyenaere, M. Ferrante, F. Offner, J. Vandesompele, and S. Ferrero. Diagnostics (Basel) 12, no. 4 (Apr 12 2022). read more ›

 2022-04-01 |
Managing Hematological Cancer Patients During the Covid-19 Pandemic: An esmo-Eha Interdisciplinary [...]

Managing Hematological Cancer Patients During the Covid-19 Pandemic: An esmo-Eha Interdisciplinary Expert Consensus
Buske, C., M. Dreyling, A. Alvarez-Larrán, J. Apperley, L. Arcaini, C. Besson, L. Bullinger, P. Corradini, M. Giovanni Della Porta, M. Dimopoulos, S. D'Sa, H. T. Eich, R. Foà, P. Ghia, M. G. da Silva, J. Gribben, R. Hajek, C. Harrison, M. Heuser, B. Kiesewetter, J. J. Kiladjian, N. Kröger, P. Moreau, J. R. Passweg, F. Peyvandi, D. Rea, J. M. Ribera, T. Robak, J. F. San-Miguel, V. Santini, G. Sanz, P. Sonneveld, M. von Lilienfeld-Toal, C. Wendtner, G. Pentheroudakis, and F. Passamonti. ESMO Open 7, no. 2 (Apr 2022): 100403.

 2022-04-01 |
Diagnosis and Management of Waldenström Macroglobulinaemia-a British Society for Haematology [...]

Diagnosis and Management of Waldenström Macroglobulinaemia-a British Society for Haematology Guideline
Pratt, G., D. El-Sharkawi, J. Kothari, S. D'Sa, R. Auer, H. McCarthy, R. Krishna, O. Miles, C. Kyriakou, and R. Owen. Br J Haematol 197, no. 2 (Apr 2022): 171-87.

 2022-03-01 |
Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas

Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas
Minson, A., C. Tam, M. Dickinson, and J. F. Seymour. Cancers (Basel) 14, no. 5 (Mar 1 2022).

 2022-03-01 |
Conditional Relative Survival in Waldenström's Macroglobulinaemia: A Population-Based Study in [...]

Conditional Relative Survival in Waldenström's Macroglobulinaemia: A Population-Based Study in the Netherlands
Amaador, K., M. J. Kersten, O. Visser, E. F. M. Posthuma, M. C. Minnema, J. M. I. Vos, and A. G. Dinmohamed. Br J Haematol 196, no. 5 (Mar 2022): 1205-08.

 2022-01-19 |
Preneoplastic Somatic Mutations Including Myd88(L265p) in Lymphoplasmacytic Lymphoma

Preneoplastic Somatic Mutations Including Myd88(L265p) in Lymphoplasmacytic Lymphoma
Rodriguez, S., J. Celay, I. Goicoechea, C. Jimenez, C. Botta, M. J. Garcia-Barchino, J. J. Garces, M. Larrayoz, S. Santos, D. Alignani, A. Vilas-Zornoza, C. Perez, S. Garate, S. Sarvide, A. Lopez, H. C. Reinhardt, Y. R. Carrasco, I. Sanchez-Garcia, M. J. Larrayoz, M. J. Calasanz, C. Panizo, F. Prosper, J. M. Lamo-Espinosa, M. Motta, A. Tucci, A. Sacco, M. Gentile, S. Duarte, H. Vitoria, C. Geraldes, A. Paiva, N. Puig, R. Garcia-Sanz, A. M. Roccaro, G. Fuerte, J. F. San Miguel, J. A. Martinez-Climent, and B. Paiva. Sci Adv 8, no. 3 (Jan 21 2022): eabl4644.

 2022-01-11 |
Determination of Myd88l265p Mutation Fraction in Igm Monoclonal Gammopathies.

Determination of Myd88l265p Mutation Fraction in Igm Monoclonal Gammopathies.
Bagratuni, T., A. Markou, D. Patseas, N. Mavrianou-Koutsoukou, F. Aktypi, C. I. Liacos, A. D. Sklirou, F. Theodorakakou, I. Ntanasis-Stathopoulos, M. Gavriatopoulou, I. P. Trougakos, E. Lianidou, E. Terpos, E. Kastritis, and M. A. Dimopoulos. Blood Adv 6, no. 1 (Jan 11 2022): 189-99.

 2022-01-01 |
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final [...]

Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis from the Randomized Phase Iii Innovate Study
Buske, C., A. Tedeschi, J. Trotman, R. García-Sanz, D. MacDonald, V. Leblond, B. Mahe, C. Herbaux, J. V. Matous, C. S. Tam, L. T. Heffner, M. Varettoni, M. L. Palomba, C. Shustik, E. Kastritis, S. P. Treon, J. Ping, B. Hauns, I. Arango-Hisijara, and M. A. Dimopoulos. J Clin Oncol 40, no. 1 (Jan 1 2022): 52-62.

 2022-01-01 |
Flow Cytometry Detection of Cd138 Expression Continuum between Monotypic B and Plasma Cells Is [...]

Flow Cytometry Detection of Cd138 Expression Continuum between Monotypic B and Plasma Cells Is Associated with Both High Igm Peak Levels and Myd88 Mutation and Contributes to Diagnosis of Waldenström Macroglobulinemia
Gayet, M., V. Leymarie, P. Derouault, E. Guérin, J. Vaidié, V. Pascal, M. Boulin, N. Dmytruk, J. Chauzeix, F. Trimoreau, N. Gachard, J. Feuillard, and D. Rizzo. Cytometry B Clin Cytom 102, no. 1 (Jan 2022): 62-69.

 2022-01-01 |
Combining Ixazomib with Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's [...]

Combining Ixazomib with Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/Ii Hovon124/Ecwm-R2 Study
Kersten, M. J., K. Amaador, M. C. Minnema, J. M. I. Vos, K. Nasserinejad, M. Kap, E. Kastritis, M. Gavriatopoulou, W. Kraan, M. E. D. Chamuleau, D. Deeren, L. W. Tick, J. K. Doorduijn, F. Offner, L. H. Böhmer, R. D. Liu, S. T. Pals, and M. A. Dimopoulos. J Clin Oncol 40, no. 1 (Jan 1 2022): 40-51.

 2021

 2021-08-11 |
Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis [...]

Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate Trial
Judith Trotman, Christian Buske, Alessandra Tedeschi, Jeffrey V Matous, David MacDonald, Constantine S Tam, Olivier Tournilhac, Shuo Ma, Steven P Treon, Albert Oriol, Jerry Ping, Eva M Briso, Israel Arango-Hisijara, Meletios A Dimopoulos

 2021-05-11 |
Obinutuzumab and Idelalisib in Symptomatic Patients with Relapsed/Refractory Waldenström Macr [...]

Obinutuzumab and Idelalisib in Symptomatic Patients with Relapsed/Refractory Waldenström Macroglobulinemia
Tomowiak, C., S. Poulain, C. Herbaux, A. Perrot, B. Mahé, P. Morel, T. Aurran, O. Tournilhac, S. Leprêtre, S. Assaad, B. Villemagne, O. Casasnovas, D. Nollet, D. Roos-Weil, S. Chevret, and V. Leblond. Blood Adv 5, no. 9 (May 11 2021): 2438-46.

 2021-02-16 |
Targeting of CXCR4 by the Naturally Occurring CXCR4 Antagonist EPI-X4 in Waldenström's Macrog [...]

Targeting of CXCR4 by the Naturally Occurring CXCR4 Antagonist EPI-X4 in Waldenström's Macroglobulinemia
Lisa Marie Kaiser, Mirja Harms, Daniel Sauter, Vijay P S Rawat, Mirco Glitscher, Eberhard Hildt, Daniel Tews, Zachary Hunter, Jan Münch, Christian Buske

 2021-02-01 |
CXCR4 in Waldenström's Macroglobulinema: chances and challenges

CXCR4 in Waldenström's Macroglobulinema: chances and challenges
Lisa Marie Kaiser, Zachary R Hunter, Steven P Treon, Christian Buske

 2020

 2020-12-08 |
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of [...]

Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial
Meletios Dimopoulos, Ramon Garcia Sanz, Hui-Peng Lee, Marek Trneny, Marzia Varettoni, Stephen Opat, Shirley D'Sa, Roger G Owen, Gavin Cull, Stephen Mulligan, Jaroslaw Czyz, Jorge J Castillo, Marina Motta, Tanya Siddiqi, Mercedes Gironella Mesa, Miquel Granell Gorrochategui, Dipti Talaulikar, Pier Luigi Zinzani , Elham Askari, Sebastian Grosicki, Albert Oriol, Simon Rule, Janusz Kloczko, Alessandra Tedeschi, Christian Buske, Veronique Leblond, Judith Trotman, Wai Y Chan, Jan Michel, Jingjing Schneider, Ziwen Tan, Aileen Cohen, Jane Huang, Constantine S Tam

 2020-11-07 |
Consensus treatment recommendations from the tenth International Workshop for Waldenström Mac [...]

Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia
Jorge J Castillo, Ranjana H Advani, Andrew R Branagan, Christian Buske, Meletios A Dimopoulos, Shirley D'Sa, Marie José Kersten, Veronique Leblond, Monique C Minnema, Roger G Owen, M Lia Palomba, Dipti Talaulikar, Alessandra Tedeschi, Judith Trotman, Marzia Varettoni, Josephine M Vos, Steven P Treon, Efstathios Kastritis

 2020-10-29 |
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: [...]

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study
Constantine S Tam, Stephen Opat, Shirley D'Sa, Wojciech Jurczak, Hui-Peng Lee, Gavin Cull, Roger G Owen, Paula Marlton, Björn E Wahlin, Ramón Garcia Sanz, Helen McCarthy, Stephen Mulligan, Alessandra Tedeschi, Jorge J Castillo, Jaroslaw Czyz, Carlos Fernández de Larrea, David Belada, Edward Libby, Jeffrey V Matous, Marina Motta, Tanya Siddiqi, Monica Tani, Marek Trneny, Monique C Minnema, Christian Buske, Veronique Leblond, Judith Trotman, Wai Y Chan, Jingjing Schneider, Sunhee Ro, Aileen Cohen, Jane Huang, Meletios Dimopoulos

 2020-08-01 |
Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 [...]

Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic
Dipti Talaulikar, Ranjana H Advani, Andrew R Branagan, Christian Buske, Meletios A Dimopoulos, Shirley D'Sa, Maria J Kersten, Veronique Leblond, Monique C Minnema, Roger G Owen, Maria Lia Palomba, Alessandra Tedeschi, Judith Trotman, Marzia Varettoni, Josephine M Vos, Steven P Treon, Efstathios Kastritis, Jorge J Castillo

 2019

 2019-12-19 |
Bruton tyrosine-kinase inhibitor on the rise: acalabrutinib in Waldenström macroglobulinemia

Bruton tyrosine-kinase inhibitor on the rise: acalabrutinib in Waldenström macroglobulinemia
Christian Buske

 2019-05-01 |
Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and [...]

Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C.

 2018

 2018-12-12 |
Bendamustine plus rituximab in newly-diagnosed Waldenström macroglobulinaemia patients. A study [...]

Bendamustine plus rituximab in newly-diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO).
Laribi K, Poulain S, Willems L, Merabet F, Le Calloch R, Eveillard JR, Herbaux C, Roos-Weil D, Chaoui D, Roussel X, Tricot S, Dupuis J, Dartigeas C, Bareau B, Bene MC, Baugier de Materre A, Leblond V.

 2018-12-07 |
How I treat rituximab refractory patients with WM.

How I treat rituximab refractory patients with WM.
Gavriatopoulou M, Ntanasis-Stathopoulos I, Kastritis E, Dimopoulos MA.

 2018-12-06 |
Ibrutinib for the treatment of Bing-Neel syndrome: A multicenter study.

Ibrutinib for the treatment of Bing-Neel syndrome: A multicenter study.
Castillo JJ, Itchaki G, Paludo J, Varettoni M, Buske C, Eyre TA, Chavez JC, Shain KH, Issa S, Palomba ML, Pasvolsky O, Simpson D, Talaulikar D, Tam CS, Tedeschi A, Ansell SM, Nayak L, Treon SP.

 2018-11-15 |
Ibrutinib and Rituximab in Waldenström's Macroglobulinemia.

Ibrutinib and Rituximab in Waldenström's Macroglobulinemia.
Dimopoulos MA, Salman Z, Buske C.

 2018-10-01 |
Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and [...]

Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C; ESMO Guidelines Committee.

 2018-09-10 |
Prognostic factors and primary treatment for Waldenström macroglobulinemia - a Swedish Lymphoma [...]

Prognostic factors and primary treatment for Waldenström macroglobulinemia - a Swedish Lymphoma Registry study.
Brandefors L, Melin B, Lindh J, Lundqvist K, Kimby E.

 2018-08-23 |
Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating [...]

Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM.
Gavriatopoulou M, Terpos E, Ntanasis-Stathopoulos I, Papasotiriou I, Fotiou D, Migkou M, Roussou M, Kanellias N, Ziogas D, Dialoupi I, Eleutherakis Papaiakovou E, Kastritis E, Dimopoulos MA.

 2018-07-19 |
Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammo [...]

Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies.
Bagratuni T, Ntanasis-Stathopoulos I, Gavriatopoulou M, Mavrianou-Koutsoukou N, Liacos C, Patseas D, Kanellias N, Migkou M, Ziogas DC, Eleutherakis-Papaiakovou E, Roussou M, Fotiou D, Terpos E, Kastritis E, Dimopoulos MA.

 2018-07-05 |
Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, [...]

Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review.
Buske C, Sadullah S, Kastritis E, Tedeschi A, García-Sanz R, Bolkun L, Leleu X, Willenbacher W, Hájek R, Minnema MC, Cheng M, Bilotti E, Graef T, Dimopoulos MA; European Consortium for Waldenström's Macroglobulinemia.

 2018-06-05 |
A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström [...]

A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
Tam CS, LeBlond V, Novotny W, Owen RG, Tedeschi A, Atwal S, Cohen A, Huang J, Buske C.

 2018-06-01 |
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.
Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia.

 2018-04-10 |
How we manage patients with Waldenström macroglobulinaemia.

How we manage patients with Waldenström macroglobulinaemia.
Simon L, Baron M, Leblond V.

 2018-02-01 |
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): [...]

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, Tournilhac O, Ma S, Oriol A, Heffner LT, Shustik C, García-Sanz R, Cornell RF, de Larrea CF, Castillo JJ, Granell M, Kyrtsonis MC, Leblond V, Symeonidis A, Kastritis E, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia.

 2017

 2017-08-02 |
Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional [...]

Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).
Durot E, Tomowiak C, Michallet AS, Dupuis J, Hivert B, Leprêtre S, Toussaint E, Godet S, Merabet F, Van Den Neste E, Ivanoff S, Roussel X, Zini JM, Regny C, Lemal R, Sutton L, Perrot A, Le Dû K, Kanagaratnam L, Morel P, Leblond V, Delmer A.

 2017-02-15 |
Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations [...]

Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel.
D'Sa S, Kersten MJ, Castillo JJ, Dimopoulos M, Kastritis E, Laane E, Leblond V, Merlini G, Treon SP, Vos JM, Lunn MP.

 2016

 2016-10-10 |
Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's [...]

Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia.
Gavriatopoulou M, Kastritis E, Kyrtsonis MC, Vassilakopoulos TP, Roussou M, Fotiou D, Migkou M, Mpakiri M, Tasidou A, Terpos E, Dimopoulos MA.

 2016-10-06 |
Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome.

Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome.
Minnema MC, Kimby E, D'Sa S, Fornecker LM, Poulain S, Snijders TJ, Kastritis E, Kremer S, Fitsiori A, Simon L, Davi F, Lunn M, Castillo JJ, Patterson CJ, Le Garff-Tavernier M, Costopoulos M, Leblond V, Kersten MJ, Dimopoulos MA, Treon SP.

 2016-07-18 |
Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobul [...]

Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia.
Leblond V, Kastritis E, Advani R, Ansell SM, Buske C, Castillo JJ, García-Sanz R, Gertz M, Kimby E, Kyriakou C, Merlini G, Minnema MC, Morel P, Morra E, Rummel M, Wechalekar A, Patterson CJ, Treon SP, Dimopoulos MA.

 2015

 2015-09-10 |
Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: [...]

Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study.
Kastritis E, Gavriatopoulou M, Kyrtsonis MC, Roussou M, Hadjiharissi E, Symeonidis A, Repoussis P, Michalis E, Delimpasi S, Tsatalas K, Tsirigotis P, Vassou A, Vervessou E, Katodritou E, Gika D, Terpos E, Dimopoulos MA.

 2015-04-09 |
Ibrutinib in previously treated Waldenström´s macroglobulinemia.

Ibrutinib in previously treated Waldenström´s macroglobulinemia.
Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, Patterson CJ, Rodig S, Zehnder JL, Aster JC, Harris NL,Kanan S, Ghobrial I, Castillo JJ, Laubach JP, Hunter ZR, Salman Z, Li J, Cheng M, Clow F, Graef T, Palomba ML, Advani RH.

 2015-03-14 |
Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström [...]

Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia.
Tedeschi A, Picardi P, Ferrero S, Benevolo G, Margiotta Casaluci G, Varettoni M, Baratè C, Motta M, Gini G, Goldaniga MC, Visco C, Zaja F, Belsito Petrizi V, Ravelli E, Gentile M, Urbano MA, Franceschetti S, Ghione P, Orsucci L, Frustaci AM, Gaidano G, Vitolo U, Morra E.

 2014

 2014-07-15 |
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: [...]

Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.
Dimopoulos MA1, Kastritis E1, Owen RG2, Kyle RA3, Landgren O4, Morra E5, Leleu X6, García-Sanz R7, Munshi N8, Anderson KC8, Terpos E1, Ghobrial IM8,Morel P9, Maloney D10, Rummel M11, Leblond V12, Advani RH13, Gertz MA3, Kyriakou C14, Thomas SK15, Barlogie B16, Gregory SA17, Kimby E18, Merlini G19,Treon SP8.

 2014-02-27 |
Guidelines on the diagnosis and management of Waldenström macroglobulinaemia.

Guidelines on the diagnosis and management of Waldenström macroglobulinaemia.
Roger G Owen, Guy Pratt, Rebecca L Auer, Rita Flatley, Charalampia Kyriakou, Michael P Lunn, Francis Matthey, Helen McCarthy, Feargal P McNicholl, Saad M Rassam, Simon D Wagner, Matthew Streetly, Shirley D'Sa; British Committee for Standards in Haematology

 2014-02-26 |
Associated cancers in Waldenström macroglobulinemia: clues for common genetic predisposition.

Associated cancers in Waldenström macroglobulinemia: clues for common genetic predisposition.
Enrica Morra, Marzia Varettoni, Alessandra Tedeschi, Luca Arcaini, Francesca Ricci, Cristiana Pascutto, Sara Rattotti, Eleonora Vismara, Laura Paris, Mario Cazzola

 2014-02-25 |
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, [...]

Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)
Meletios A Dimopoulos, Ramón García-Sanz, Maria Gavriatopoulou, Pierre Morel, Marie-Christine Kyrtsonis, Eurydiki Michalis, Zafiris Kartasis, Xavier Leleu, Giovanni Palladini, Alessandra Tedeschi, Dimitra Gika, Giampaolo Merlini, Efstathios Kastritis, Pieter Sonneveld

 2013

 2013-11-22 |
New ESMO guidelines for WM published! Waldenstrom's macroglobulinaemia: ESMO Clinical Practice [...]

New ESMO guidelines for WM published! Waldenstrom's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Buske C, Leblond V, Dimopoulos M, Kimby E, Jäger U, Dreyling M; ESMO Guidelines Working Group.

 2013-11-21 |
Presentations on WM at ASH 2013 in New Orleans from our consortium on: Elevated Von Willebrand [...]